

# Hannes Hagström

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6450604/publications.pdf>

Version: 2024-02-01

102  
papers

8,716  
citations

101543

36  
h-index

45317

90  
g-index

102  
all docs

102  
docs citations

102  
times ranked

8021  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , 2015, 61, 1547-1554.	7.3	1,683
2	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	7.3	1,294
3	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 1265-1273.	3.7	730
4	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	1.3	575
5	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	8.4	507
6	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
7	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , 2021, 70, 1375-1382.	12.1	307
8	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. <i>Hepatology Communications</i> , 2018, 2, 48-57.	4.3	200
9	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1008-1016.	8.1	194
10	Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. <i>Gastroenterology</i> , 2020, 158, 200-214.	1.3	121
11	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. <i>Clinical Epidemiology</i> , 2021, Volume 13, 21-41.	3.0	111
12	Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. <i>Journal of Hepatology</i> , 2020, 73, 1023-1029.	3.7	108
13	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , 2022, 71, 1867-1875.	12.1	105
14	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
15	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. <i>Annals of Internal Medicine</i> , 2019, 171, 318.	3.9	95
16	Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. <i>Hepatology</i> , 2021, 74, 2410-2423.	7.3	91
17	Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. <i>JHEP Reports</i> , 2021, 3, 100256.	4.9	87
18	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1950-1956.e1.	4.4	84

#	ARTICLE	IF	CITATIONS
19	Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 268-274.	3.9	80
20	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 197-204.	3.9	75
21	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	17.8	72
22	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	4.4	71
23	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. <i>Journal of Hepatology</i> , 2016, 65, 363-368.	3.7	68
24	High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. <i>Gut</i> , 2018, 67, 1536-1542.	12.1	68
25	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	3.7	66
26	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	1.5	60
27	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. <i>Liver International</i> , 2019, 39, 1098-1108.	3.9	59
28	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1255.	4.8	58
29	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. <i>Hepatology Communications</i> , 2018, 2, 1299-1305.	4.3	56
30	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	3.9	54
31	Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. <i>Journal of Hepatology</i> , 2018, 68, 505-510.	3.7	52
32	Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. <i>Gut</i> , 2021, 70, 170-179.	12.1	49
33	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. <i>Liver International</i> , 2018, 38, 2082-2090.	3.9	47
34	Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. <i>Current Hepatology Reports</i> , 2017, 16, 152-157.	0.9	45
35	Validity of administrative codes associated with cirrhosis in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1205-1210.	1.5	43
36	Maternal obesity increases the risk and severity of NAFLD in offspring. <i>Journal of Hepatology</i> , 2021, 75, 1042-1048.	3.7	41

#	ARTICLE	IF	CITATIONS
37	Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3720.	2.4	40
38	Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1461-1468.	4.4	37
39	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2769-2775.e4.	4.4	37
40	Waist/Hip Ratio Better Predicts Development of Severe Liver Disease Within 20 Years Than Body Mass Index: A Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1294-1301.e2.	4.4	36
41	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1427-1434.	1.5	36
42	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	1.5	32
43	Risk of hepatic and extrahepatic cancer in <scp>NAFLD</scp>: A population-based cohort study. <i>Liver International</i> , 2022, 42, 820-828.	3.9	29
44	Nonalcoholic Fatty Liver Disease and Risk of Dementia. <i>Neurology</i> , 2022, 99, .	1.1	28
45	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1348-1354.	2.3	27
46	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	3.6	27
47	Transient liver elastography in normal pregnancy – a longitudinal cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 761-765.	1.5	26
48	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , 2021, 3, 100218.	4.9	26
49	Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. <i>Journal of Internal Medicine</i> , 2022, 291, 824-836.	6.0	26
50	Risk of cardiovascular disease and loss in life expectancy in NAFLD. <i>Hepatology</i> , 2022, 76, 1495-1505.	7.3	26
51	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 885-894.	3.9	25
52	A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 75, 98-107.	3.7	25
53	Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 918-929.e8.	4.4	24
54	The prediction of colorectal cancer using anthropometric measures: A Swedish population-based cohort study with 22 years of follow-up. <i>United European Gastroenterology Journal</i> , 2019, 7, 1250-1260.	3.8	23

#	ARTICLE	IF	CITATIONS
55	A Dynamic Aspartate to Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1021-1035.	4.3	23
56	Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 439.	2.0	22
57	Alcohol, smoking and the liver disease patient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 537-543.	2.4	21
58	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	4.4	21
59	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. <i>Hepatology</i> , 2018, 68, 625-633.	7.3	20
60	Incidence of ICD-Based Diagnoses of Alcohol-Related Disorders and Diseases from Swedish Nationwide Registers and Suggestions for Coding. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1433-1442.	3.0	19
61	Low Bone Mineral Density and Risk for Osteoporotic Fractures in Patients with Chronic Pancreatitis. <i>Nutrients</i> , 2021, 13, 2386.	4.1	17
62	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	2.5	17
63	Alcohol consumption in patients with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2012, 18, 3105.	3.3	17
64	Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	16
65	The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 465-476.	3.8	15
66	Predictive Capacity for Mortality and Severe Liver Disease of the Relative Fat Mass Algorithm. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2619-2620.	4.4	13
67	Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2636-2647.e13.	4.4	13
68	Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 978-983.	1.5	12
69	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. <i>PLoS ONE</i> , 2018, 13, e0202651.	2.5	11
70	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	3.9	11
71	Etiologies and outcomes of cirrhosis in a large contemporary cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 727-732.	1.5	11
72	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 177-189.	6.0	11

#	ARTICLE	IF	CITATIONS
73	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	3.7	11
74	Risk Behaviors Associated with Alcohol Consumption Predict Future Severe Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2014-2023.	2.3	10
75	Association between temperature, sunlight hours and alcohol consumption. <i>PLoS ONE</i> , 2019, 14, e0223312.	2.5	9
76	Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study. <i>Journal of Internal Medicine</i> , 2022, 292, 492-500.	6.0	9
77	Lifestyle Factors in Late Adolescence Associate With Later Development of Diverticular Disease Requiring Hospitalization. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1474-1480.e1.	4.4	8
78	Vascular Complications in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3720.	2.4	7
79	Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 198-211.	3.8	6
80	Pregnancy Outcomes in Women With Autoimmune Hepatitis – A Nationwide Population-based Cohort Study With Histopathology. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 103-114.e10.	4.4	6
81	Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 789-796.	3.7	5
82	Is teenage heavy drinking more hazardous than we thought?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 603-605.	3.0	4
83	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	1.5	4
84	Wide-field endoscopic submucosal dissection for the treatment of Barrett's esophagus neoplasia. <i>Endoscopy International Open</i> , 2021, 09, E727-E734.	1.8	4
85	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1420-1426.	1.6	4
86	Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: Data from the Swedish Obese Subjects study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2675-2676.e2.	4.4	3
87	Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1359-1361.e2.	4.4	3
88	Editorial: severe outcomes are rare in pregnancy with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1017-1018.	3.7	2
89	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
90	Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	2

#	ARTICLE	IF	CITATIONS
91	External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. JHEP Reports, 2021, 3, 100343.	4.9	2
92	“Considerations in the search for under-reported alcohol consumption in NAFLD”, Journal of Hepatology, 2022, , .	3.7	2
93	Reply to: “A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits”, Journal of Hepatology, 2018, 69, 252-253.	3.7	1
94	Reply. Hepatology Communications, 2019, 3, 848-848.	4.3	1
95	Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?. Alimentary Pharmacology and Therapeutics, 2020, 51, 1204-1205.	3.7	1
96	Three-fold Increased Risk of Death in Budd-Chiari Syndrome Compared to Matched Controls: A Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 995-1004.e9.	4.4	1
97	Less is more? Screening for steatosis in older populations. Hepatology, 2023, 77, 350-351.	7.3	1
98	Reply. Hepatology, 2016, 64, 310-311.	7.3	0
99	SAT-416-Transient elastography in normal pregnancies: A prospective cohort study. Journal of Hepatology, 2019, 70, e817-e818.	3.7	0
100	Reply to: “Reduced steatosis and weight as a result of specific diets or the dietitian themselves”, JHEP Reports, 2021, 3, 100366.	4.9	0
101	A new model for estimation of significant fibrosis in primary care. SAFE to use?. Hepatology, 2023, 77, 18-19.	7.3	0
102	Hepatocellular carcinoma in Stockholm, Sweden 2003–2018: a population-based cohort study. Scandinavian Journal of Gastroenterology, 0, , 1-9.	1.5	0